Company Overview - GSK is focused on four major therapeutic areas and has upgraded its guidance to the top end for the year [2] - The Specialty business is a significant driver of growth, particularly in Oncology, Respiratory, Immunology, and Inflammation [2] - The HIV business is performing well, especially with the introduction of a new 2-month long-acting treatment [2] Financial Performance - GSK has a long-term sales guidance of over GBP 40 billion by 2031 [2] - The company achieved 13 Phase III positive readouts last year, indicating strong R&D performance [2] Future Outlook - GSK is on track for five major approvals and four launches this year, with key products including Blenrep and depemokimab for respiratory conditions [3] - The company positions itself as growth-oriented with a robust pipeline and upcoming product launches [3]